Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Applied Therapeutics, Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The active prosecution is centralized, involving 1 distinct examiner and 1 distinct art unit. This indicates that the company's current legal focus at the USPTO is likely limited to a specific therapeutic candidate or a patent family.
The busiest examiner for the portfolio is ROZOF, TIMOTHY R, who is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions for Applied Therapeutics, Inc. is also 1, this examiner is the individual overseeing the company's active applications. The outcome of the pending office action will determine the immediate progress in the Biotechnology & Pharmaceuticals sector.
The involvement of the distinct art unit suggests that the technical scope of the current prosecution is narrow. Practitioners can focus their efforts on the distinct examiner, ROZOF, TIMOTHY R, to address the outstanding office action. This streamlined profile means that the company's active patent pipeline is currently concentrated in an interaction within the USPTO.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| MCMILLIAN, KARA RENITA | 1 | 30.7% | +37.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | MCMILLIAN, KARA RENITA | 67d overdue |
| 17951342 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | ROZOF, TIMOTHY R | 76d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17951342 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | ROZOF, TIMOTHY R | 1625 | §112 | Non-Final OA | 76d | Pending | Sep 23, 2022 |
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | MCMILLIAN, KARA RENITA | 1623 | §103 | Non-Final OA | 67d overdue | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial